Zhengye Biotechnology Holding Limited (ZYBT)

NASDAQ: ZYBT · USD

$1.34

+0.01 (+0.8%)· Recorded snapshot

Market cap	63.5M
Revenue (ttm)	16.6M
Net income (ttm)	-10M
EPS (ttm)	-$0.21
Shares out	47.4M
Volume	4,773.666

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 16.6M
Net income (ttm): -10M
EPS (ttm): -$0.21
Market cap: 63.5M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Mantenere

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-11-04 14:30 UTC

Forward P/En/a

P25 13.4P50 20.2P75 35.7

Trailing P/En/a

P25 15.4P50 25.8P75 43.5

ROE-25.2

P25 -113.8P50 -46.5P75 -0.9

ROIC-21.4

P25 -68.5P50 -27.1P75 1.8

Benchmarks · 1M

All ZYBT indicators

Market & fundamental data

Available fields

202

Groups with data

Currency

CNY

Showing 202 of 202 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001975641
Company name	Zhengye Biotechnology Holding Limited
Country	China
Country code	US
CUSIP number	G989MS101
Earnings date	2026-12-11
Earnings time	amc
Employees	269
Employees change	-8
Employees growth	-2.89%
Enterprise value	$66.8M
Exchange	NASDAQ
Financial currency	CNY
Financial report date	2025-12-31
First seen	2026-05-09
Fiscal year end	December
Founded	2004
Industry	Drug Manufacturers - Specialty & Generic
IPO date	2025-01-07
Is primary listing	Yes
Is SPAC	No
ISIN number	KYG989MS1016
Last 10-K release date	2026-04-28
Last earnings date	2026-04-28
Last refreshed	2026-11-04
Last stock split type	Never
Market cap	$63.5M
Market cap category	Micro-Cap
Next earnings date	2026-12-11
Options	No
Price	$1.34
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-11-03
Symbol	ZYBT
Website	https://www.jlzybio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-15.72%
EV/FCF	36.2x
EV/Sales	4.02x
FCF / EV yield	2.76%
FCF yield	2.91%
Industry forward P/E	14.04x
Industry P/E	107.82x
P/B ratio	1.78x
P/FCF ratio	34.4x
P/OCF ratio	31.8x
P/S ratio	3.82x
Price / tangible book value	2.28x
Sector forward P/E	23.32x
Sector P/E	49.47x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	-60.59%
EBITDA margin	-38.35%
FCF margin	10.59%
Gross margin	20.51%
Operating margin	-60.59%
Pretax margin	-61.77%
Profit margin	-59.97%
Profit per employee	$-37,090
Revenue per employee	$61,846
ROA	-9.48%
ROCE	-22.31%
ROE	-25.17%
ROIC	-21.37%
ROIC (5Y)	4.57%
Tax / revenue	9.53%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	0
FCF growth	-55.12%
FCF growth (Q)	82.72%
Gross profit growth	-73.86%
Gross profit growth (Q)	-90.99%
Gross profit growth 3Y	-45.55%
Net income growth years	0
OCF growth	-67.52%
OCF growth (Q)	3.58%
OCF growth 3Y	-8.38%
Revenue growth	-37.56%
Revenue growth (Q)	-40.89%
Revenue growth (QoQ)	-13.31%
Revenue growth 3Y	-23.53%
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-150,966
Depreciation and amortization	$3.9M
EBIT	$-10.1M
EBITDA	$-6.4M
EPS	$-0.21
FCF per share	$0.04
Financing cash flow	$4.6M
Free cash flow	$1.8M
Gross profit	$3.4M
Income taxes	$1.6M
Investing cash flow	$-1.8M
Net borrowing	$-1.8M
Net cash flow	$4.5M
Net income	$-10M
Operating income	$-10.1M
Revenue	$16.6M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	8.39
Book value per share	$0.75
Debt / equity	0.24
Debt / FCF	5.82
Interest coverage	-20.74
Long-term assets	$41.8M
Long-term liabilities	$508,123
Net cash (debt)	$-3.3M
Net cash / market cap	-5.22%
Net debt / equity	0.08
Net debt / FCF	1.8
Piotroski F-Score	2
Property, plant and equipment	$35.5M
Shareholders' equity	$43.9M
Tangible book value	$27.9M
Tangible book value per share	$0.59
Total assets	$62.4M
Total cash	$7.4M
Total debt	$10.7M
Total liabilities	$18.6M

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.25
Current assets	$20.6M
Current liabilities	$18M
Current ratio	1.14
Inventory turnover	1.9
Net working capital	$4.4M
Quick ratio	0.58
Working capital	$2.4M
Working capital turnover	0.59

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-3.69%
Dividend yield	0%
Shareholder yield	-3.69%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$1.25
1D price change	0.75%
1M price change	8.07%
1M total return	8.07%
1W price change	-6.94%
1W total return	-6.94%
1Y price change	-45.53%
1Y return CAGR	-45.55%
1Y total return	-45.53%
20-day SMA	$1.43
200-day SMA	$1.16
3M price change	0.75%
3M total return	0.75%
50-day SMA	$1.45
50-day SMA vs 200-day SMA	50over200
52-week high	$8.01
52-week high date	2026-07-20
52-week low	$0.62
52-week low date	2026-07-02
6M price change	45.65%
6M total return	45.65%
After-hours change	-2.75%
After-hours close	$1.34
After-hours price	$1.30
All-time high	$14.30
All-time high date	2025-04-29
All-time low	$0.62
All-time low date	2026-07-02
Average true range (ATR)	$0.18
Average volume	1.8M
Beta (1Y)	0.87
Beta (2Y)	-0.29
Change from 52-week high	-83.27%
Change from 52-week low	117.71%
Change from all-time high	-90.63%
Change from all-time low	117.71%
Change from open	3.88%
Day's gap	-3.01%
Dollar volume	$6,397
High price	$1.42
Low price	$1.29
Monthly RSI	44.08
Open price	$1.29
Position in 52-week range	38.46%
Premarket change	-0.75%
Premarket close	$1.34
Premarket price	$1.33
Premarket volume	301
Previous close	$1.33
Price vs 150-day SMA	7.46%
Price vs 20-day SMA	-6.56%
Price vs 200-day SMA	15.72%
Price vs 50-day SMA	-7.59%
Relative volume	0
Return from IPO open	-64.46%
Return from IPO price	-66.5%
RSI	45.58
Sharpe ratio	0.84
Sortino ratio	8.16
Volume	4.8K
Weekly RSI	48.66
YTD price change	16.52%
YTD total return	16.52%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	6.3M
Float percentage	13.21%
Shares change (QoQ)	0.14%
Shares change (YoY)	3.69%
Shares held by institutions	0.27%
Shares outstanding	47.4M
Short % of float	1.08%
Short % of shares	0.14%
Short ratio	0 days

Deeper analysis on ZYBT

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this ZYBT report

Is a complete ZYBT research report available?

No complete published report is available for Zhengye Biotechnology Holding Limited (ZYBT) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Zhengye Biotechnology Holding Limited (ZYBT)

Price

Financial snapshot

Fair-value bridge

Latest news · ZYBT

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All ZYBT indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on ZYBT

Frequently asked questions